HUTCHMED Presentations at 2024 ASCO Annual Meeting | Company Announcement
Investegate announcements from HUTCHMED Presentations at 2024 ASCO Annual Meeting
Source: investegate.co.uk
📰 Targeted Agents News
Targeted Agents News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Targeted Agents. Real-time updates on events, politics, business and more.
AstraZeneca advances scientific leadership in hematology at ASH 2023
CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of promising early pipeline New,...
Source: marketscreener.com
Hidden Costs Of Arthritis Treatment Include Liver Damage,
Recent research finds risks to rheumatoid arthritis treatment, signaling importance of medical documentation with disabilities when seeking Social Security...
United States Disability Financial Solutions Rheumatoid Arthritis Support Network Research On Liver Damage Ticket To Work Program Disability Financial Services
Source: globenewswire.com
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses and seven patients with prolonged stable disease Efficacy and tolerability data from dose escalation and... | May 25, 2023
United States Julie Schneiderman Christian Marsolais Philippe Dubuc Communications Corporate Affairs Theratechnologies Inc
Source: marketscreener.com
Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
HOUSTON--(BUSINESS WIRE)--May 25, 2023--
United States Imran Alibhai Sara Manning Apostoliam Tsimberidou American Society Of Clinical Oncology Tvardi Therapeutics Inc
Source: wsiltv.com
Theratechnologies to Present Preliminary Safety and
Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR) and seven patients with prolonged stable disease (SD)...
United States Philippe Dubuc Christian Marsolais Julie Schneiderman American Society Of Clinical Oncology Theratechnologies Inc
Source: globenewswire.com
Stock Market | FinancialContent Business Page
FinancialContent fully hosted finance channel
United States Philippe Dubuc Christian Marsolais Julie Schneiderman University Of Texas Md Anderson Cancer Center Theratechnologies Inc
Source: financialcontent.com
Rain Therapeutics Announces a Poster Presentation at the
NEWARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology...
Comunidad Autonoma De Cataluna Vijayag Tirunagaru Jordyn Temperato Bob Yedid Head Of Research Rain Therapeutics Inc
Source: globenewswire.com
Enosi Therapeutics to Present at the ENA 2022 Symposium on Molecular Targets and Cancer Therapeutics in Barcelona
/PRNewswire/ -- Enosi Therapeutics, a drug research and development company focused on providing industry-leading therapeutics for cancer and autoimmune...
United States Marc Feldmann Lasker Jeff Huitt H Michael Shepard European Organization For Research National Cancer Institute
Source: prnewswire.com
Skin Cancer Drugs Global Market Estimated To Grow At 15% Rate
The Business Research Company’s Skin Cancer Drugs Global Market Report 2022: Market Size, Trends, And Forecast To 2026
Source: einnews.com